| Literature DB >> 32389361 |
Julian Hercun1, Christopher Koh2, Theo Heller2.
Abstract
Half a century after its discovery, hepatitis delta remains a pertinent global health issue with a major clinical impact in endemic regions and an underestimated prevalence worldwide. Hepatitis delta virus infection follows a challenging clinical course and is responsible for significant liver-related morbidity. Although the only currently available treatment (pegylated interferon) does not provide consistent results, emerging therapeutic options are promising. This article explores the epidemiology, natural history, as well as current and potential therapeutic options for hepatitis delta virus infection. Published by Elsevier Inc.Entities:
Keywords: Chronic liver disease; Hepatitis B; Hepatitis D; Investigational treatments
Year: 2020 PMID: 32389361 DOI: 10.1016/j.gtc.2020.01.004
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN: 0889-8553 Impact factor: 3.806